HGF/c-Met is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-25. Numbers and descriptions here follow the published literature rather than marketing material.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Temgicoluril is used in Latvia and Russia, as a pharmaceutical drug to treat anxiety and to prevent or reduce anxiety, unrest, fear, internal emotional tension and irritability, reduce neuroses and neurotic disorders, heartburns of non-coronary heart disease origin. These effects are not accompanied with relaxation of muscle tone and impaired coordination of movement, suppression of mental and physical activity, so the drug can be used without interruption of work or school. Temgicoluril does not have a direct effect on sleep, however, it enhances the effectiveness of sleep medicines and normalizes the course of disturbed sleep. Temgicoluril alleviates or eliminates the manifestations of nicotine dependence that occur after smoking cessation. Although temgicoluril does not cause mood swings or euphoria, habituation, nor addiction, withdrawal syndrome has been observed.
18 January – The BBC's Laura Kuenssberg reports that the Prime Minister has chaired a series of "mini-cabinet" meetings, along with the Chancellor, Foreign Secretary and Business Secretary, in an attempt to plan "for what might come" in terms of the effect on the UK during the Second Trump Presidency. 19 January – Foreign Secretary David Lammy tells the BBC the prime minister will visit the United States within weeks to meet incoming US president Donald Trump. Jeremy Corbyn and John McDonnell agree to be interviewed under caution by police following a pro-Palestinian rally in London. The police are investigating what they say was "a coordinated effort by organisers to breach conditions imposed on the event". 21 January – Marcus Bokkerink is dismissed as chair of the Competition and Markets Authority amid concerns the group is not focussed enough on economic growth; Doug Gurr replaces him on a temporary basis. First Minister of Wales Eluned Morgan tells the Senedd she is lobbying the UK government to give the Welsh Government powers over the Crown Estate in Wales, after a UK government minister suggested otherwise. 25 January – Sinn Féin lifts its suspension on Belfast City Councillor JJ Magee following an investigation by the Local Government Commissioner for Standards. 28 January – Labour's Stephen Timms is reprimanded for attending a Muslim Council of Britain dinner despite official government advice being to not engage with the organisation.
=== Lifestyle === According to a 2018 systematic review based on studies that implemented 8 to 14 week-long exercise programs, there is currently insufficient scientific evidence regarding either the beneficial or harmful effects of physical exercise in people with cirrhosis on all-cause mortality, morbidity (including both serious and non-serious adverse events), health-related quality of life, exercise capacity and anthropomorphic measures. These conclusions were based on low to very low quality research, which imposes the need to develop further research with higher quality, especially to evaluate its effects on clinical outcomes.
== See also == Curculin, a sweet protein from Malaysia with taste-modifying activity Miraculin, a protein from West Africa with taste-modifying activity Monellin, a sweet protein found in West Africa Stevia, a non-nutritive sweetener up to 150 times sweeter than sugar Lugduname, a sweetening agent up to 300,000 times sweeter than sugar
==== Supralingual ==== Supralingual administration is achieved by placing the drug above the tongue. It is often the route of administration of choice when one would like the drug to bypass or alleviate the first pass effect on the drug after oral delivery.
Sources: en.wikipedia.org
== Metabolism == In the case of ET/SRTX binding to a receptor and creation of a receptor-ligand complexes in various tissues, a very slow pace of dissociation is observed. In experiments conducted on rats, half-time of SRTX-b in the ileum is about 7 min (with comparison of 2 hours in case of ET-3), while in the cerebellum, the t1/2 values are more than 2–3 hours for both SRTX-b and ET-1, and in case of ET-3, the dissociation rate is negligible. Iodinated SRTX-b binds specifically to preparations of atrial membranes with a maximum binding capacity of 110 fmol per mg of protein and a dissociation constant (KD) of 3–5 nM. SRTX-a, SRTX-b and STRX-c inhibit binding of iodinated SRTX-b in the atrium at mean inhibitory concentrations (IC50) of 30, 25 and 100 nM, respectively. Other binding experiments have also shown that 125I-SRTX-b recognizes sites in a rat cerebellum KD = 3.5 nM and cerebral cortex KD=0.3nM. Furthermore, it has been shown that:
=== Atlantic === The fish maw trade in Brazil has grown significantly since fishermen pivoted from the shark's fin trade; the Brazilian government banned shark finning in 2012, and has introduced other restrictions on shark fishing since. Between 2015 and 2018, Brazil was the largest exporter of fish maw to Hong Kong at 3,300 tonnes (3,600 short tons), valued at HK$3 billion; 95% of exported maws came from Para, Brazil. Brazilian export of fish byproducts, including fish maw, increased by 398% from 2012 to 2020; 97% of fish byproducts were exported to China in 2021. Mirroring worldwide trends, Sciaenidae maw fetches the highest price at market in Brazil; Ariidae maw, although being significantly larger, is frequently sold in unsorted bulk (Portuguese: ariru).
Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD) as a recommended first-line treatment. It may also be used for chronic neuropathic pain. It is taken orally (swallowed by mouth). It is also available as the salt venlafaxine besylate (venlafaxine benzenesulfonate monohydrate) in an extended-release formulation (Venbysi XR). Common side effects include loss of appetite, constipation, dry mouth, dizziness, sweating, insomnia, drowsiness and sexual problems. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction. Severe side effects include an increased risk of suicide, mania, and serotonin syndrome. Antidepressant withdrawal syndrome may occur if stopped. A meta-analysis of randomized trials in depression found an increased rate of serious adverse events, particularly sexual dysfunction and anorexia, and several non-serious adverse effects, including nervousness, asthenia, and tremor. There are concerns that use during the later part of pregnancy can harm the baby. Venlafaxine's mechanism of action is not entirely clear, but it seems to be related to the potentiation of the activity of some neurotransmitters in the brain.
He launched tirades against international critics, particularly, United States President Barack Obama, the US government, the United Nations, and the European Union, which expressed condemnation to his unprecedented war on drugs that led to the deaths of about 3,300 people, half of which were killed by unknown assailants, and the arrest of 22,000 drug suspects and surrender of about 731,000 people.
In 2024, the Council of Europe adopted the Framework Convention on Artificial Intelligence and Human Rights, Democracy and the Rule of Law, the first legally binding international treaty governing artificial intelligence.
Sources: en.wikipedia.org
=== Internet shutdown === Several human rights organisations including Human Rights Watch (HRW) condemned the al-Burhan-led TMC for shutting down the internet in June 2019. A spokesperson, Shamseldin Kabbashi, stated that the internet would be shut down for a long time because it represented a threat to national security. The move was described by HRW as a "gross violation of human rights". International media saw this as a sign of dictatorship and condemned the act. Many see it as an attempt to hide what al-Burhan's allied militia, known as the Janjaweed, were doing in Khartoum to delay uploading evidence of the violations that took place on 3 June 2019 and in the days that followed.
By 1919, the company was able to commercialize production of citric acid from this source. The company developed expertise in fermentation technology as a result. These skills were applied to the deep-submergence mass production of penicillin, an antibiotic, during World War II in response to the need to treat injured Allied soldiers. The company also embarked on a global soil collection program related to improving production yields of penicillin which ultimately resulted in 135,000 samples. On June 2, 1942, the company incorporated under the Delaware General Corporation Law.
By 1980, the BSAP comprised about 46,000 personnel; 11,000 professionals (about 60% black), and the remainder reservists (mostly white). The organisation's rank structure was unique, with different levels of seniority existing for black and white officers respectively. Until 1976, black officers could rise no further than sub-inspector, while the commissioned ranks were all-white. Limitations on black aspirations were removed in 1976. The first promotion of African members to previously European-only ranks occurred on 21 October 1976 with 23 Sub-Inspectors and 8 Detective Sub-Inspectors, a week later, being promoted to Patrol Officers.
Alexander, Crown Prince of Yugoslavia (Serbian: Александар Карађорђевић, Престолонаследник Југославије, romanized: Aleksandar Karađorđević, Prestolonaslednik Jugoslavije; born 17 July 1945), is the head of the House of Karađorđević, the former royal house of the defunct Kingdom of Yugoslavia and its predecessor the Kingdom of Serbia. Alexander is the only child of King Peter II and Princess Alexandra of Greece and Denmark. He held the position of crown prince in the Democratic Federal Yugoslavia for the first four-and-a-half months of his life, until the declaration of the Federal People's Republic of Yugoslavia later in November 1945, when the monarchy was abolished. In public he claims the crowned royal title of "Alexander II Karadjordjevic" (Serbian: Александар II Карађорђевић, Aleksandar II Karađorđević) as a pretender to the throne. Born and raised in the United Kingdom, he enjoys close relationships with his relatives in the British royal family. His godparents were King George VI of the United Kingdom and his daughter, the then-Princess Elizabeth (later Queen Elizabeth II). Through his father, Alexander is a descendant of Queen Victoria, through his great-great-grandfather Prince Alfred, Duke of Saxe-Coburg and Gotha, Victoria's second eldest son. Maternally, he is also a descendant of Queen Victoria, through his great-great-grandmother Victoria, German Empress, Victoria's eldest daughter. Alexander is known for his support of constitutional monarchism and his humanitarian work.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.